SCHEMBL5651747

SCHEMBL5651747

CCN(CC)CCCNC(=O)c1ccc(-c2nc3ccc(C(F)(F)F)cc3[nH]2)c(C)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 2/20 0.53
METAP2 P50579 1/20 0.47
F9 P00740 1/20 0.47
HDAC6 Q9UBN7 4/20 0.45
HDAC4 P56524 2/20 0.45
HDAC2 Q92769 2/20 0.45
HDAC8 Q9BY41 2/20 0.45
GAA P10253 2/20 0.45
MCHR1 Q99705 1/20 0.44
TP53 P04637 1/20 0.43
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HDAC3 O15379 2/20 0.42
HDAC7 Q8WUI4 2/20 0.42
HDAC10 Q969S8 2/20 0.42
LMNA P02545 1/20 0.42
KMT2A Q03164 1/20 0.42
NPBWR1 P48145 1/20 0.41
CHEK1 O14757 1/20 0.41
HDAC1 Q13547 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5651756 0.93 FLT3 (0.47) FLT3METAP2F9HDAC6HDAC4
SCHEMBL5650980 0.91 FLT3 (0.53) FLT3F9HDAC6HDAC4HDAC2
SCHEMBL5653988 0.89 FLT3 (0.51) FLT3METAP2F9HDAC6HDAC4
SCHEMBL5653244 0.88 FLT3 (0.51) FLT3METAP2F9HDAC6HDAC4
SCHEMBL5653261 0.88 FLT3 (0.55) FLT3F9HDAC6HDAC4HDAC2
SCHEMBL5651055 0.88 FLT3 (0.68) FLT3METAP2F9HDAC6HDAC3
SCHEMBL5650786 0.86 METAP2 (0.47) FLT3METAP2HDAC6HDAC4HDAC2
SCHEMBL5650796 0.84 HTT (0.45) METAP2HDAC6HDAC4HDAC2HDAC8
SCHEMBL5653615 0.84 HDAC6 (0.46) HDAC6GAATP53HTTSMN1; SMN2
SCHEMBL5649255 0.84 PRSS12 (0.50) HDAC6GAATP53HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220769-B2 Azolylbenzamides and analogues and their use for treating osteoporosis NIKEM RESEARCH S.R.L. (IT) 2007-05-22 US disclosed
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis 3-V BIOSCIENCES, INC. 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis NR0B2, NR0B1, NCOR1 FLT3 1968/4885METAP2 3311/4885F9 4095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.